Bleeding related adverse events associated with antiviral treatment in influenza patients: A disproportionality analysis using FDA adverse event reporting system (FAERS)

被引：0
|
作者：
Sarker, Jyotirmoy [1 ]
Carkovic, Emir [2 ]
Lee, Todd A. [3 ]
机构：
[1] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
[2] Univ Illinois, Coll Pharm, Chicago, IL USA
[3] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1036
引用
收藏
页码：486 / 487
页数：2
相关论文
共 50 条
  • [41] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
    Wen, Ming-Tao
    Li, Jia-Cheng
    Lu, Bo-Wen
    Shao, Hua-Rong
    Ling, Pei-Xue
    Liu, Fei
    Li, Gang
    Luo, Di
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [42] Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
    Kong, Wenqiang
    Mao, Wei
    Zhang, Lin
    Wu, Yanyan
    FRONTIERS IN PEDIATRICS, 2023, 10
  • [43] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System DatabaseA Disproportionality Analysis
    Behrooz K. Shamloo
    Pankdeep Chhabra
    Andrew N. Freedman
    Arnold Potosky
    Jennifer Malin
    Sheila Weiss Smith
    Drug Safety, 2012, 35 : 507 - 518
  • [44] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database A Disproportionality Analysis
    Shamloo, Behrooz K.
    Chhabra, Pankdeep
    Freedman, Andrew N.
    Potosky, Arnold
    Malin, Jennifer
    Smith, Sheila Weiss
    DRUG SAFETY, 2012, 35 (06) : 507 - 518
  • [45] Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
    Zhu, Jinfeng
    Hu, Mianda
    Liang, Yingshi
    Zhong, Mingjun
    Chen, Zilin
    Wang, Zhenjie
    Yang, Yujia
    Luo, Ziyi
    Zeng, Wenqi
    Li, Jiahui
    Du, Yikuan
    Liu, Yi
    Yang, Chun
    HELIYON, 2024, 10 (14)
  • [46] Disproportionality analysis of adverse events associated with asfotase alfa: a post-marketing study using the FDA Adverse Event Reporting System
    Wang, Wen
    Wang, Zhe
    Chen, Qianxiu
    Sun, Haixia
    Fu, Zongchao
    Han, Jing
    Lv, Hao
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [47] Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system
    Chen, Chen
    Wu, Bin
    Zhang, ChenYu
    Xu, Ting
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 95
  • [48] Adverse event profiles of CDK4/6 inhibitors: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database
    Tian, Xiaojiang
    Chen, Lin
    Chen, Yonghong
    Zhang, Ni
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [49] Reports of adverse events related with second generation antipsychotics in children in the FDA adverse event reporting system (FAERS)
    Zapata, Lorenzo Villa
    Bibbs, Janese
    Crapps, Mariah
    Lumbreras, Ainhoa Gomez
    Malone, Daniel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 579 - 580
  • [50] Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
    Li, Yun
    Li, Hang
    Xiang, Zhongyuan
    HELIYON, 2024, 10 (06)
12345